Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
STEMLINE THERAPEUTICS INC (STML)
|
Add to portfolio |
|
|
|
| Price: |
$12.15
| | Metrics |
| OS: |
52.5
|
M
| |
-48
|
% ROE
|
| Market cap: |
$638
|
M
| |
-61
|
% ROIC
|
|
Net cash:
|
$152
|
M
| |
$2.89
|
per share
|
|
EV:
|
$486
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($73.1)
|
M
| |
|
|
|
EBIT
|
($73.2)
|
M
| |
|
|
| EPS |
($1.63)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 43.2 | 0.5 | 0.9 | 1.0 | 0.7 | 0.3 | 0.1 | 0.0 |
| Revenue growth | 8543.4% | -44.3% | -13.7% | 59.2% | 95.1% | 372.2% | | |
| Cost of goods sold | 4.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 38.3 | 0.5 | 0.9 | 1.0 | 0.7 | 0.3 | 0.1 | 0.0 |
| Gross margin | 88.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 66.8 | 39.1 | 19.2 | | | | | |
| Research and development | 50.7 | 47.7 | 50.2 | 27.9 | 29.5 | 21.2 | 16.2 | 3.4 |
| General and administrative | | | | 12.1 | 8.8 | 8.1 | 7.9 | 3.1 |
| EBIT | -79.2 | -86.3 | -68.6 | -38.9 | -37.6 | -29.0 | -24.0 | -6.5 |
| EBIT margin | -183.4% | -17257.3% | -7632.9% | -3734.1% | -5752.9% | -8646.3% | -33773.9% | |
| Pre-tax income | -76.8 | -85.0 | -67.8 | -38.3 | -37.2 | -28.8 | -24.2 | -6.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -76.8 | -85.0 | -67.8 | -38.3 | -37.2 | -28.8 | -24.2 | -6.3 |
| Net margin | -177.7% | -17004.9% | -7551.6% | -3678.2% | -5693.4% | -8598.6% | -34079.6% | |
| |
| Diluted EPS | ($1.83) | ($2.99) | ($2.94) | ($2.15) | ($2.15) | ($2.23) | ($2.35) | ($1.82) |
| Shares outstanding (diluted) | 42.1 | 28.4 | 23.1 | 17.8 | 17.3 | 12.9 | 10.3 | 3.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|